Notch proteins are transcriptional activators expressed first as transmembrane heterodimeric surface receptors. Four mammalian Notch proteins, Notch1-Notch4, and five Notch ligands, Jagged 1 and 2 and Delta-like 1, 3 and 4, have been identified 1 . After ligand binding, Notch undergoes proteolytic processing, including a final cleavage by g-secretase to release its intracellular signaling peptide, which translocates to the nucleus and activates transcription of target genes 2, 3 . Pharmacological g-secretase inhibitors (GSIs) effectively prevent activation of all Notch receptors by inhibiting this final enzymatic cleavage 4 . Although the function of Notch in hematopoiesis and thymocyte development has been well documented 5 , Notch also acts in synergy with T cell receptor signaling to sustain T cell activation and interferon-g (IFN-g) production 6, 7 , providing evidence Notch is also important in regulating peripheral T cell responses.
Activated CD4 + T cells can further differentiate into T helper type 1 (T H 1) or T H 2 cells 8 . Studies have suggested Notch may influence both T H 1 and T H 2 polarization 9, 10 . During terminal maturation, T H 1 and T H 2 subsets acquire the ability to express and respond to a 'signature' cytokine profile. IFN-g, tumor necrosis factor and interleukin 12 (IL-12) are cytokines associated with T H 1 responses, whereas T H 2 responses are characterized mainly by IL-4, IL-5 and IL-13. Although its regulation remains poorly defined, expression of the canonical T H 1 transcription factor T-bet, encoded by Tbx21, is both necessary and sufficient to drive CD4 + T H 1 differentiation and secretion of the primary T H 1 effector cytokine IFN-g 11, 12 . IFN-g in turn positively regulates Tbx21 expression 'downstream' of the IFN-g receptor through a pathway mediated by the transcription factor STAT1 (ref. 13) . Whether IFN-g acts to initiate or to sustain Tbx21 expression has not been fully resolved. Reports have argued for the existence of an IFN-g receptor-STAT1-independent means of inducing Tbx21 (refs. 9, 14, 15) , and abrogation of T-bet signaling but not of STAT1 provides protection from experimental autoimmune encephalomyelitis (EAE) 16, 17 , a T H 1-mediated model of multiple sclerosis 18 . Those observations led us to ask whether Notch facilitates T H 1 differentiation by directly regulating Tbx21 and whether blocking of Notch signaling using GSIs can effectively abrogate T H 1 polarization and alter the disease progression of EAE.
RESULTS

Blocking Notch activation prevents T H 1 polarization
In vivo, T helper cell differentiation is orchestrated by multiple cell types in a complex cytokine milieu; however, we used an in vitro T helper cell polarization assay to focus on CD4 + T cell-intrinsic effects of GSIs 19 (Fig. 1) . We first examined the polarization of CD4 + cells isolated from mice with transgenic expression of a Notch1 antisense construct (Notch1AS mice) 20 . Notch1AS mice express 30-40% less Notch1 protein than do wild-type mice 20 . We cultured Notch1AS CD4 + cells for 3 weeks in neutral or T H 1-or T H 2-inducing conditions and, after restimulating the cells, analyzed the supernatants by enzyme-linked immunosorbant assay (ELISA) for secreted IFN-g and IL-4. Notch1AS CD4 + cells produced less IFN-g than did wildtype controls when cultured in T H 1-polarizing conditions, but retained their ability to adopt a T H 2 phenotype (Fig. 1a) . These data agree with earlier work showing no overt defects in T H 2 profiles for CD4 + cells from transgenic mice with conditional deletion of Notch1 in CD4 + cells 21 . Those mice with conditional deletion of Notch1 in CD4 + cells also mount effective T H 1 responses in vivo to clear infection with Leishmania major 21 , consistent with our data from Notch1AS mice demonstrating decreased but not abrogated IFN-g (Fig. 1a) . These data suggest that functional redundancy of other Notch family members may compensate for diminished Notch1 signaling in T H 1 conditions.
Next we treated C57BL/6 mice for 3 d in vivo with orally administered GSI, or with dimethyl sulfoxide (DMSO) as control, before isolating CD4 + cells. After culturing the cells for 24 h in polarizing conditions, we assayed total Notch1 protein as an indicator of GSI efficacy. We detected total Notch1 protein in whole-cell lysates of CD4 + cells from DMSO-treated mice regardless of polarization, with slightly more expression in T H 1-polarized cultures. By comparison, total Notch1 protein was nearly undetectable in CD4 + cells from GSI-treated mice (Fig. 1d) . We did parallel in vitro polarization assays of CD4 + cells and analyzed supernatants for IFN-g and IL-4. Compared with controls, CD4 + cells from GSI-treated mice produced much less IFN-g in T H 1-inducing conditions but retained their ability to secrete IL-4 ( Fig. 1b) , in agreement with our results using Notch1AS CD4 + cells. Finally, we pretreated CD4 + cells from C57BL/6 mice in vitro with GSI before T helper cell polarization. Consistent with results using Notch1AS mice and mice treated with GSI in vivo, in vitro treatment of CD4 + cells abrogated IFN-g but not IL-4 production (Fig. 1c) . Collectively these data show that blockade of Notch signaling using GSI either in vivo or in vitro prevents T H 1 differentiation and IFN-g secretion. However, in the absence of Notch signaling, T H 2 polarization seems able to proceed through Notchindependent mechanisms.
Lineage commitment in developing T helper cells requires multiple cell divisions for the implementation of genetic programming that confers a T H 1 or T H 2 cell fate 22, 23 . With increasing numbers of cell divisions, the ability to successfully 'reprogram' a T H 1 cell toward a T H 2 fate, and vice versa, diminishes 24, 25 . GSI remained biologically active for approximately 24 h (data not shown), after which Notchinhibitory properties were lost. This short-lived activity suggested to us that using GSI to block early activation of Notch in CD4 + cells during in vitro polarization produced profound and long-lasting effects on their ability to adopt a T H 1 but not a T H 2 fate. Therefore, we examined the initial 96 h of T helper cell differentiation at 24-hour intervals in polarization assays of GSI-and DMSO-pretreated CD4 + cells. A single pretreatment with GSI did not affect proliferation during the first 96 h (Fig. 1e) . Flow cytometry of polarized CD4 + cells stained with 5-carboxyfluorescein diacetate succinamidyl ester (CFSE), whose fluorescence intensity is diminished by half with each cell division, showed similar CFSE expression (Fig. 1e) as well as percent proliferating cells (Fig. 1f ) GSI-and DMSO-treated cultures at all time points. Thus, the notable differences in IFN-g production found in GSI-pretreated polarization assays (Fig. 2a) could not be attributed to differences in proliferation in GSI-and DMSOtreated cultures.
GSI pretreatment differentially affects protein expression
We next analyzed cytokine expression at 24-hour intervals during the early stages of polarization. Pretreatment with GSI did not seem to alter IL-4 production; however, in contrast to DMSO controls, IFN-g secretion was abrogated as early as 48 h after GSI pretreatment of T H 1-polarized cultures and remained low throughout the culture period (Fig. 2a) . In contrast, treatment of developing CD4 + T H 1 and T H 2 cells with GSI after 48 h in culture did not affect IFN-g production (Fig. 2b) . These data confirm that the first 24-48 h of T helper cell differentiation represent a critical time period during which blocking Notch activation inhibits T H 1 polarization without perturbing T H 2 cell fate choices. Cytokines influence transcription through signals relayed by STAT molecules 26 . Phosphorylated STAT1 (phospho-STAT1) mediates IFN-g receptor signaling 27 , whereas phospho-STAT4 signals downstream of the IL-12 receptor 28, 29 , which is itself transcriptionally regulated by T-bet in T H 1 cells 13 . In similar way, phospho-STAT6 transduces signals through the IL-4 receptor in T H 2 cells 30 . We assessed expression of phospho-STAT1, phospho-STAT4 and phospho-STAT6 in polarization assays of GSI-and DMSO-pretreated CD4 + cells during the first 96 h of culture. GSI pretreatment effectively prevented phosphorylation of STAT4 within 24 h, whereas phosphorylation of STAT6 was reduced but not totally abrogated (Fig. 2c) . We did not detect phospho-STAT1 expression at any time point, regardless of pretreatment or polarizing conditions (data not shown), although it is possible that temporal expression of phospho-STAT1 is outside the time points we examined.
After T cell activation, Notch1 is upregulated 7 and further upregulates its own expression 31 . Thus, inhibition of g-secretase prevents the generation of endogenous intracellular Notch (Notch IC ) as well as total Notch expression. Again using Notch1 protein expression as an indicator of GSI efficacy, we found Notch1 was upregulated in DMSO-pretreated CD4 + cells in all culture conditions at 24 h and remained detectable in T H 1-polarized cultures throughout the 96-hour period examined (Fig. 2c) . We detected Notch1 IC at 24 and 48 h in T H 1-polarized, DMSO-pretreated CD4 + cells. In contrast, we detected no Notch1 or Notch1 IC in GSI-pretreated cultures regardless of polarizing conditions. Thus, by monitoring expression and cleavage of Notch1 protein, we demonstrated that GSI effectively inhibits CD4 + T H 1 differentiation by modulating Notch protein expression as well as STAT4 phosphorylation. Phosphorylation of STAT6 seemed less sensitive to GSI pretreatment, consistent with the observation that T H 2 differentiation and IL-4 production remain intact in the absence of Notch activation.
Signaling through Notch receptors is initiated by ligand binding. Using RT-PCR, we assessed the presence of Notch ligands on CD4 + cells pretreated with DMSO or GSI and cultured for 24 h in neutral IFN-γ (ng/ml) conditions. We detected transcripts encoding the Notch ligands Jagged 1, Jagged 2 and Delta-like 1 in both DMSO-and GSI-treated cells, thus confirming that our in vitro polarization assay is a complete system with which to study CD4 + T cell-intrinsic effects of Notch signaling during T helper cell differentiation (Fig. 2d) .
To determine whether GSI inhibits T H 1 polarization through effects on CD44, another cleavage substrate of g-secretase 32 , we evaluated CD44 expression on DMSO-and GSI-pretreated CD4 + cells. Regardless of pretreatment or polarizing conditions (Supplementary Methods online), CD44 expression remained equivalently high at 96 h. Furthermore, the ability of CD44 to bind its cognate ligand hyaluronic acid was not impaired in either T H 1-or T H 2-polarized cells pretreated with GSI, even though IFN-g secretion was abrogated in GSI-pretreated T H 1-polarized cultures ( Supplementary Fig. 1 online) . These data indicate that although GSI pretreatment of in vitropolarized CD4 + cells abrogates IFN-g production, these effects may be independent of its effects, if any, on CD44 signaling. Along with the results from in vitro polarization of Notch1AS CD4 + cells (Fig. 1a) , these data provide additional supporting evidence that GSI prevents T H 1 polarization by inhibiting Notch activation and not through 'promiscuous' effects on CD44.
Notch activation correlates with Tbx21 expression
Early attenuation of responses after GSI pretreatment suggested that its use might instill heritable alterations to genetic programs driving T H 1 polarization. T helper cell differentiation is complex and is subject to multiple levels of regulation. Expression of the transcription factor T-bet is indispensable for T H 1 commitment and is considered a 'signature' of T H 1 cells 11 . Tbx21 induction in CD4 + cells has been correlated with exposure to the Notch ligand fusion protein Delta-1-Fc 9 . Although that observation suggested involvement of Notch signaling in Tbx21 expression, direct regulation of Tbx21 by Notch has not yet been demonstrated. As early as 24 h after pretreatment of CD4 + cells with GSI, the abundance of Tbx21 transcript in developing T H 1 cells was comparable to that of DMSO-treated T H 2 cells (Fig. 3a) . By 48 h, Tbx21 expression was extinguished altogether in GSIpretreated T H 1 cells and in DMSO-treated T H 2 cells and correlated closely with IFN-g production in these cultures (Fig. 3a,b) . 48 h of retroviral infection with a construct encoding activated Notch1 (N1 IC ; Supplementary Fig. 2 online), Tbx21 expression was restored both in DMSO-pretreated T H 2 cells and GSI-pretreated T H 1 cells (Fig. 3c,d ). There was increased IFN-g secretion in supernatants of GSI-treated T H 1 cells showing Notch1 IC -induced re-expression of Tbx21 (data not shown). These data confirm that Notch protein activation is an essential early event in T H 1 polarization and suggest that although functional redundancy among Notch proteins may exist, signaling through Notch1 IC is sufficient to induce Tbx21 expression.
Notch1 can directly regulate Tbx21 transcription Analysis of the Tbx21 promoter remains incomplete, although STAT1 binding sites are present and positively regulate its transcription 13 . We examined approximately 1 kilobase of genomic DNA upstream of the mouse Tbx21 start site and identified multiple putative binding sites for CSL, a transcription factor important in Notch-mediated signaling ( Supplementary Fig. 3 online) . In the absence of activated Notch, CSL forms complexes with the transcriptional corepressors SMRT and SKIP to repress transcription from CSL binding sites 33 . When Notch signaling is initiated, however, Notch IC binds to the CSL complex, displacing the SMRT-SKIP corepressors, and recruits the coactivator Mastermind-like 1, among others, to convert CSL to a transcriptional activator 34 . To analyze Tbx21 regulation by Notch1, we stably expressed amino acids 1,759-2,556 of N1 IC or empty vector in the DO11.10 T cell hybridoma (called 'DO11.10-N1 IC ' and 'DO11.10-EV' , respectively). We did chromatin immunoprecipitation assays 35 using antibody to CSL (anti-CSL) or anti-Notch1 to precipitate proteins crosslinked to DNA. After releasing proteins, we used PCR to amplify two separate regions containing 'candidate' CSL binding motifs upstream of the Tbx21 start site ( Supplementary Fig. 3 online) .
Immunoprecipitation with anti-CSL showed CSL bound to putative consensus sites both in DO11.10-EV and DO11.10-N1 IC cells, suggesting it may bind constitutively to these sites (Fig. 4a, top left) . Consistent with the function of CSL as a transcriptional repressor, Tbx21 expression was barely detectable in DO11.10-EV cells (Fig. 4b,  lanes 1 and 2) . However, chromatin immunoprecipitation analysis using anti-Notch1 showed that Notch1 was detected in complex with CSL at these sites only in DO11.10-N1 IC cells (Fig. 4a, top right) . In agreement with the idea that N1 IC can bind CSL and convert it to an activator, DO11.10-N1 IC cells had more Tbx21 expression than did 6 8 4 VOLUME 6 NUMBER 7 JULY 2005 NATURE IMMUNOLOGY DO11.10-EV cells (Fig. 4b, lanes 3 and 4) . Furthermore, DO11.10-N1 IC cells secreted more IFN-g, demonstrating a biological effect of N1 IC -mediated Tbx21 induction (Fig. 4c) . To assess the physiological relevance of CSL-N1 IC interaction at these candidate CSL binding sites, we designed primers to amplify a second, nearby region in the Tbx21 promoter that also contained putative CSL binding motifs ( Supplementary Fig. 3 online) . Immunoprecipitation with anti-CSL did not detect CSL bound to these sites; thus, this second region was not amplified by PCR (Fig. 4a, bottom left) . Notably, there was also no amplification of this region after immunoprecipitation with antiNotch1 (Fig. 4a, bottom right) , suggesting that in the absence of CSL binding, Notch1 is not recruited independently to these sites. The observation that N1 IC associates with CSL only at specific CSL binding sites strongly suggests physiological relevance of this interaction. These data demonstrate that N1 IC can form a complex with its nuclear binding partner CSL at candidate CSL binding sites in the Tbx21 promoter of DO11.10-N1 IC cells to directly and positively regulate Tbx21 transcription and concomitant IFN-g production. These data provide a T cell-intrinsic mechanism for Notch1-mediated regulation of CD4 + T H 1 cell differentiation. -151) ) and continued the GSI treatment throughout the disease course. We monitored mice for 20 d, then measured in vivo T H 1-mediated recall responses to PLP(139-151) challenge using a delayed-type hypersensitivity (DTH) assay. Mice treated intraperitoneally with GSI had a significant delay in the onset of disease compared with that of DMSO-treated control mice (P o 0.001; mean time of onset, 14.3 7 0.7 d versus 16.6 7 0.7 d for DMSO versus GSI; Fig. 5a ). Both GSI-treated groups showed substantial reduction in clinical symptoms compared with that of DMSO-treated mice, regardless of administration or length of pretreatment before disease induction (Fig. 5a,b) . Additionally, GSItreated mice challenged in vivo with PLP(139-151) had a significantly reduced recall response compared with that of DMSO-treated control mice (P o 0.0001; Fig. 5c,d) , further demonstrating the attenuation of T H 1-mediated responses. When we stimulated splenocytes from GSI-treated mice ex vivo with PLP(139-151), we noted decreased proliferation and reduction of T H 1-associated cytokines, including IFN-g, compared with that of splenocytes from control mice ( Supplementary Fig. 4 online) .
GSI ameliorates symptoms of EAE
In a study of extended duration, we administered DMSO or GSI orally beginning 1 week before the induction of disease and continuing for 6 weeks. This treatment regimen also significantly reduced both the incidence (P o 0.05) and the severity (P o 0.05) of relapsing EAE (Table 1) . Furthermore, when we examined the spinal cords of mice from each treatment group, there was a notable paucity of inflammatory lesions in tissues of mice treated with GSI (Fig. 5e,f) compared with that of control mice (Fig. 5g,h) . Notably, we found no mortality or morbidity due to the inhibitor in the GSI-treated mice. Finally, when we induced a more severe EAE by coupling PLP (139-151) injection with administration of pertussis toxin, oral administration of GSI again delayed onset and substantially reduced the severity of disease compared with that of controls (mean clinical score, 4.6 versus 2.9 for DMSO versus GSI; P o 0.05; Fig. 5i ). Attenuated in vivo DTH reactions together with diminished IFN-g production after ex vivo peptide challenge suggest the inhibitory action of GSI administered in vivo successfully targets developing T H 1 cells. These data suggest treatment with GSI effectively ameliorates clinical symptoms of EAE in a mouse T H 1-mediated model of multiple sclerosis.
DISCUSSION
Studies using STAT1-deficient transgenic mice have indicated the existence of an IFN-g receptor-STAT1-independent pathway for initiating Tbx21 transcription. Although STAT1-deficient mice do not mount T H 1 responses sufficient to clear infection with Toxoplasma gondii, Tbx21 transcript are still detected early during infection 15 . In other studies, abrogation of T-bet signaling by introduction of Tbx21 small interfering RNA 16 or deletion of Tbx21 (ref. 17) has been shown to protect from EAE, whereas STAT1 deficiency does not 17 , again suggesting STAT1-independent regulation of T H 1 responses. Our data showing induction of Tbx21 in developing CD4 + T H 2 cells after retroviral infection with N1 IC also provide evidence of an IFN-g receptor-STAT1-independent pathway for Tbx21 initiation, as these T H 2-polarized cultures contained anti-IFN-g and thus prevented signaling through the IFN-g receptor-STAT1 axis.
Also, the first 24-48 h of T helper cell differentiation seem to represent a critical 'window' during which Notch activation may be essential for the adoption of a T H 1 cell fate by CD4 + cells. CD4 + cells induce Tbx21 expression when incubated with a Delta-1-Fc fusion protein 9 . Those experiments 9 did not distinguish which Notch family member is responsible for Tbx21 induction or whether its regulation was direct or indirect. However, that observation agrees with our data demonstrating direct positive regulation of Tbx21 by Notch in complex with CSL and showing that N1 IC is sufficient to mediate this process. Although the location of regulatory sequences is often not conserved among species, candidate CSL binding sites are present within a 1-kilobase region upstream of the transcriptional start site in the human TBX21 promoter region (data not shown). Thus, we propose a working model whereby CSL may bind constitutively to specific sites in the Tbx21 promoter region to repress Tbx21 transcription in the absence of activated Notch. After its activation, Notch binding in complex with CSL may convert CSL to a transcriptional activator, possibly through the recruitment of additional coactivators. A CSLdeficient mouse strain has been described that 'preferentially' adopts a T H 1 phenotype 40 . In agreement with our model, loss of CSL from putative binding sites may derepress the Tbx21 promoter, possibly making it accessible to positive regulation by additional transcription factors.
Genetic studies have identified Notch and the b-amyloid precursor protein as dominant cleavage targets for the presenilin-containing g-secretase complex 41 . Notch and amyloid precursor protein may compete as substrates for processing by g-secretase 42 . It is reasonable to assume that in the immune system, Notch proteins represent a principal target of g-secretase and that GSI works mainly to inhibit Notch activation. However, additional substrates of g-secretase have been identified, and the adhesion molecule CD44 represents another target of interest in immune cells 32 . We did not evaluate CD44 signaling in our in vivo EAE model; however, our in vitro data suggest the contribution of CD44 to T H 1 polarization is minimal. Consistent with that conclusion, studies of the T H 1-mediated response to challenge with Mycobacterium tuberculosis in CD44-deficient transgenic mice have shown that although pulmonary neutrophil influx increases in infected mice, no defect is noted in the trafficking of lymphocytes to the lungs or in the generation of T H 1-mediated protective immunity 43 . Our in vitro studies have demonstrated a distinct cell-intrinsic effect of GSI on CD4 + cells; however, we cannot rule out the possibility of as-yet-undefined effects of GSI on additional substrates or cell types that may have contributed to its ability to attenuate T H 1 responses in our in vivo EAE studies. Experiments to evaluate possible additional mechanisms of GSI action are needed.
There is no consensus regarding the contribution that Notch may make in directing T helper cell differentiation. Involvement of Delta-1-mediated signaling in T helper cell differentiation has been described. However, whereas one study suggested it promotes T H 1-mediated clearance of L. major in a susceptible host 9 , another purported it to be immunoprotective in a cardiac allograft model mediated by CD8 + T cells 44 . Similarly, there are contradictory reports as to how Notch1 may influence T helper cell differentiation. One published report suggested no overt function for Notch1 in T H 2 differentiation 21 , whereas another concluded Notch1 is critical in driving T H 2 differentiation, even in the absence of STAT6 (ref. 10) .
Those conflicting data may result from the use of disparate N1 IC constructs as well as different animal models. We have compared two very similar N1 IC constructs, differing in their N-terminal sequence by only 11 amino acids. We found that transduction with one induced production of the transcription factor NF-kB and of IFN-g, whereas introduction of the other had no effect (data not shown). Thus, for this study we used a human N1 IC construct (consisting of amino acids 1,759-2,550) that closely resembles the endogenously generated, biologically relevant form of human Notch1 IC (amino acids 1,744-2,556) in both its size and its downstream signaling capabilities, as measured by induction of NF-kB 20 . Other studies have used N1 IC constructs containing the entire transmembrane domain and extending for approximately 36 amino acids into the extracellular domain (amino acids 1,701-2,556) 10 . When studying the effects of active Notch, it is difficult to evaluate the biological relevance of constructs containing extraneous sequences not normally present in endogenously generated Notch IC . The first CSL binding site is in close proximity to the N terminus of cleaved Notch and, physiologically, it is unmasked only after g-secretase cleavage. We would argue that in lieu of 'active' N1 IC , use of a construct containing extracellular and transmembrane sequences but without a leader peptide that allows it to be efficiently inserted into the membrane and activated by g-secretase complicates data interpretation and makes comparison with expression of a constitutively active, intracellular construct difficult. We believe data from our in vivo and in vitro GSI studies as well as from our Notch1AS transgenic mice provide convincing evidence that blocking Notch activation prevents polarization toward a T H 1 phenotype. Furthermore, our retroviral infection experiments strongly complement those data and demonstrate that N1 IC is sufficient to direct T H 1 differentiation and Tbx21 expression in CD4 + cells. Additionally, our data do not refute earlier work suggesting Notch may be involved in T H 2 differentiation 10 . Our data do suggest that in the absence of Notch signaling, there may be Notchindependent means of driving a T H 2 response, whereas there seem to be no Notch-independent means of inducing a T H 1 response. The direct consequence of our findings is that pharmacological suppression of Notch signaling in humans may result in selective inhibition of T H 1 differentiation while sparing T H 2 differentiation and it could therefore be used to manipulate the immune response in this direction when this is therapeutically desirable.
Another issue deserving further investigation is the possibility of redundant effects among the Notch proteins. GSI treatment entirely abrogates Notch signaling by preventing the cleavage of all four Notch receptors 45 . Our Notch1AS mouse data suggest that downregulation of Notch1 can substantially reduce IFN-g production, and our 'rescue' experiments indicate that expression of N1 IC is sufficient to reverse the effects of GSI. However, as all four Notch proteins are capable of binding CSL 45 , it is possible that other Notch proteins also participate in T-bet regulation, either physiologically or as a compensatory effect when Notch1 is completely lost, as in gene-targeted cells.
Effective modulation of T H 1-mediated autoimmunity represents a considerable clinical challenge. An emerging paradigm suggests that inhibition of T-bet expression is an effective means of achieving this end 16, 17 . Here we have provided strong evidence that GSI-mediated inhibition of Notch signaling confers CD4 + T cell-intrinsic alterations, including abrogation of Tbx21 induction, which attenuate biological responses and mitigate the paralysis and demyelination characteristic of EAE. A phase I clinical trial using GSI for the treatment of Alzheimer disease has been completed 46 . As early indications suggest that GSIs are well tolerated, our data would indicate potential therapeutic value for GSIs in treating the early relapsing-remitting phase of multiple sclerosis. Additional studies will show whether GSIs would be equally effective in treating other T H 1-mediated autoimmune diseases.
METHODS
EAE induction and GSI treatment. Mice were housed in animal care facilities at Northwestern University (Chicago, Illinois) or at the University of Massachusetts Amherst (Amherst, Massachusetts) and were cared for in compliance with institutional guidelines. The GSI administered in vivo, LY-411,575 (a mixture of four diasteriomers of a small molecule inhibitor of g-secretase), was synthesized as described 47 and was administered orally (10 mg/kg/d dissolved in DMSO, resuspended in 50 ml strawberry KoolAid) or intraperitoneally (5 mg/kg/d, dissolved in DMSO) to 6-week-old female SJL/J mice beginning 1 d (oral) or 3 d (intraperitoneal) before EAE induction and continuing throughout disease course. Control mice received DMSO orally in KoolAid or DMSO intraperitoneally, as appropriate. Relapsing EAE was induced with 50 mg PLP(139-151) (HSLGKWLGHPDKF; Peptides International) per mouse, emulsified in complete Freund's adjuvant (4 mg/ml of M. tuberculosis H37RA; Difco) and distributed in 100-ml subcutaneous injections in the hind flanks. Active EAE was induced with 100 mg PLP(139-151) emulsified in complete Freund's adjuvant, plus 200 ng pertussis toxin administered intraperitoneally on day of induction and 48 h later. GSI (10 mg/kg/d) or DMSO was administered orally beginning 1 week before induction and throughout the disease course. Clinical scores were assigned as follows: 0, no abnormality; 1, limp tail or foot; 2, limp tail and hind limb weakness; 3, partial hind limb paralysis; 4, complete hind limb paralysis; and 5, moribund. For the DTH assay, mice were challenged with 10 mg of priming peptide, and the response was measured 24 h later. For histology, spinal cord sections were fixed in 4% paraformaldehyde and were embedded in paraffin, and sections were stained with periodic acid Schiff for the evaluation of pathology.
In vitro cell assays. All antibodies and recombinant cytokines were purchased from BD Pharmingen unless indicated otherwise. For proliferation assays and LiquidChip cytokine analysis, pooled splenocytes from GSI-or DMSO-treated mice were stimulated for 96 h with various concentrations of PLP(139-151). Wells were pulsed with 3 H[thymidine] for the final 24 h of culture. Supernatants were collected and analyzed at 36 h for IFN-g and IL-4 secretion using a LiquidChip kit (Beadlyte Mouse Multicytokine Detection System I; UpState Biotechnologies) according to the manufacturer's directions. For all in vitro polarization assays, the IMag magnetic bead system (mouse anti-CD4 DM particles, for direct magnetic separation; BD Pharmingen) was used to isolate naive CD4 + T cells (more than 95% purity). For full polarization, 2.25 Â 10 6 cells/ml were pretreated in vitro at 37 1C for 15 min with 0.1% DMSO or with GSI (50 mM zIL-CHO (a small peptide inhibitor of g-secretase) in DMSO) before being added to 12-well plates precoated with 1 mg/ml each of anti-CD3 plus anti-CD28. Cultures were pulsed 24 h later with 200 U/ml of recombinant human IL-2, were expanded on day 8 and lifted, and were restimulated with plate-bound anti-CD3 plus anti-CD28 on day 19, and supernatants were collected on day 20 for ELISA. The following combinations of antibodies and cytokines were added at the time of plating to induce polarization: T H 1, 10 mg/ml of anti-IL-4 plus 1 ng/ml of IL-12; T H 2, 10 mg/ml of anti-IFN-g plus 10 ng/ml of IL-4; neutral, no polarizing antibodies or cytokines. For 96-hour polarization assays, CD4 + T cells were isolated and treated as described above, but supernatants were collected at various time points without restimulation. Supernatants were analyzed in triplicate by standard ELISA for the secretion of IFN-g and IL-4 with paired capture and detection antibodies. For CFSE analysis, CD4 + T cells were labeled with 3 mM CFSE (Molecular Probes) before GSI or DMSO pretreatment and were polarized as described above. Fluorescence was measured with a FACSCalibur and was analyzed with CellQuest software (BD Immunocytometry Systems). For immunoblot analysis, 30 mg of protein from whole-cell lysates was resolved by SDS-PAGE, transferred to nitrocellulose membranes, blocked with 5% nonfat dry milk in 0.5% Tween in PBS, probed overnight with primary antibody, washed, probed with horseradish peroxidase (HRP)-conjugated secondary antibody and developed with enhanced chemiluminescence (ECL) Western Blotting Detection Reagents (Amersham Biosciences). Blots were sequentially stripped with Restore Western Blot Stripping Buffer (Pierce), following the manufacturer's instructions, and were reprobed as above. Antibodies included anti-Notch1 (rabbit C-20; Santa Cruz Biotechnology), anti-cleaved Notch1 (Val1744; Cell Signaling Technology), anti-phospho-STAT4 (Zymed), anti-phospho-STAT6 (Cell Signaling Technology) and anti-phospho-STAT1 (Tyr 701; Santa Cruz Biotechnology).
RT-PCR and retrovirus infection. For RT-PCR, total RNA was isolated from CD4 + T cells polarized as described above using RNA-BEE (Tel-Test), following the manufacturer's directions. Reverse-transcriptase methods were used to generate cDNA, and transcripts of Tbx21 and the gene encoding the zinc finger transcription factor GATA-3 (Gata3) were amplified by PCR. Transcripts of glyceraldehyde phosphodehydrogenase (Gapd) were amplified as a loading control. Primers were as follows: Tbx21 forward, 5¢-TGAAGCCCACACTCC TACCC-3¢, and reverse, 5¢-GCGGCATTTTCTAGTTGGG-3¢; Gata3, forward, 5¢-TCTCACTCTCGAGGCAGCATGA-3¢, and reverse, 5¢-GGTACCAATCTC GCCGCCACAG-3¢; and Gapd forward, 5¢-AATTCAACGGCACAGTCAAAG CCGAGAATG-3¢, and reverse, 5¢-GCGGCACGTCAGATCCACGCAGGAC-3¢. Primers for Delta-like 1, Jagged 1 and Jagged 2 have been described 48 . For retrovirus infections, CD4 + T cells were polarized for 48 h as described, then were subjected to one round of infection by replacement of 200 ml of culture supernatant with 200 ml of retroviral supernatants from Phoenix-Eco packaging cells transfected with the bicistronic pMX vector, containing an internal riobosomal entry site allowing expression of two proteins from a single promoter: pMX human CD8-EV (empty vector) or pMX human CD8-N1 IC (N1 IC (activated human Notch1), amino acids 1,759-2,556). Cells were cultured an additional 48 h in polarizing conditions, then RNA was isolated and RT-PCR was done using the primers described above. Infection efficiency was monitored by expression of human CD8 (as an indicator of N1 IC expression, which is transcribed from the same promoter), using anti-human CD8-phycoerythrin and analysis with a FACSCalibur plus CellQuest software (BD Immunocytometry Systems).
Chromatin immunoprecipitation. The Chromatin Immunoprecipitation (ChIP) Assay Kit (17-295; Upstate Cell Signaling Solutions) was used for these analyses, but salmon sperm DNA-protein G agarose (Upstate Cell Signaling Solutions) was substituted for the beads provided. DO11.10 cells stably expressing bicistronic pMX human CD8-EV or a pMX human CD8-N1 IC construct were treated with formaldehyde to crosslink protein to DNA, then were immunoprecipitated with anti-CSL (anti-RBP-Jk (an antibody that recognizes CSL), clone K0043; Institute of Immunology) or anti-Notch1 (C-20; Santa Cruz Biotechnology). Isotype controls were as follows: for anti-RBP-Jk, purified rat monoclonal immunoglobulin G1 (IgG1; clone 43414.11; R&D Systems); for Notch1, normal rabbit IgG (control IgG, sc-207; Santa Cruz Biotechnology). After 'de-crosslinking' and sonication, two regions of the Tbx21 promoter containing putative CSL binding sites were amplified by PCR. Primer set 1 (327 base pairs (bp)) was forward, 5¢-CACAGCCCC TACCCCCAATACGAA-3¢, and reverse, 5¢-CCCCCAGCCCCGAGGATGATG-3¢ (À259 bp to À984 bp); primer set 2 (340 bp) was forward, 5¢-CTGGGCA TACAGGAGGCAGCAACAAAT-3¢, and reverse, 5¢-GTCCCCTCACC CCG CCACCTTG-3¢ (À235 bp to À577 bp). PCR conditions were as follows: 95 1C for 5 min, 95 1C for 1 min, 58 1C for 45 s and 72 1C for 1 min (35 cycles) and 72 1C for 5 min. For IFN-g production, stably transfected DO11.10-EV and DO11.10-N1 IC cells were left unstimulated or were stimulated for 5 h with 80 nM phorbol myristate acetate and 0.5 mM calcium ionophore, then supernatants were collected and IFN-g was measured by ELISA.
Note: Supplementary information is available on the Nature Immunology website.
